Cargando…

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

BACKGROUND: In patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular carcinoma (HCC). We aimed to investigate whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Y. Linda, van Hyfte, Grace, Özbek, Umut, Reincke, Marlene, Gampa, Anuhya, Mohamed, Yehia I., Nishida, Naoshi, Wietharn, Brooke, Amara, Suneetha, Lee, Pei-Chang, Scheiner, Bernhard, Balcar, Lorenz, Pinter, Matthias, Vogel, Arndt, Weinmann, Arndt, Saeed, Anwaar, Pillai, Anjana, Rimassa, Lorenza, Naqash, Abdul Rafeh, Muzaffar, Mahvish, Huang, Yi-Hsiang, Kaseb, Ahmed O., Kudo, Masatoshi, Pinato, David J., Ang, Celina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971987/ https://www.ncbi.nlm.nih.gov/pubmed/36865801 http://dx.doi.org/10.3389/fonc.2023.1128569

Ejemplares similares

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
por: Muhammed, Ambreen, et al.
Publicado: (2021)

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
por: D’Alessio, Antonio, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
por: Sharma, Rohini, et al.
Publicado: (2022)

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
por: Marinelli, Brett, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
por: Marie, Mona A., et al.
Publicado: (2022)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
por: Pinato, David J., et al.
Publicado: (2020)

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
por: Joerg, Vincent, et al.
Publicado: (2023)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications
por: Amara, Suneetha, et al.
Publicado: (2022)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort
por: Pomej, K., et al.
Publicado: (2023)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Progressive changes in platelet counts and Fib-4 scores precede the diagnosis of advanced fibrosis in NASH patients
por: Zijlstra, Michael K, et al.
Publicado: (2023)

Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience
por: de Castro, Tiago, et al.
Publicado: (2022)

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients
por: Balcar, Lorenz, et al.
Publicado: (2023)

Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy
por: Scheiner, Bernhard, et al.
Publicado: (2023)

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
por: Jun, Tomi, et al.
Publicado: (2021)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital
por: Pomej, Katharina, et al.
Publicado: (2021)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

The Mechanism of Enhanced Insulin Amyloid Fibril Formation by NaCl Is Better Explained by a Conformational Change Model
por: Muzaffar, Mahvish, et al.
Publicado: (2011)

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Effect of a Best Practice Alert on Birth-Cohort Screening for Hepatitis C Virus
por: Khan, Mohammad Qasim, et al.
Publicado: (2021)

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2023)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Spontaneous Heparin-Induced Thrombocytopenia and COVID-19 Infection
por: Amara, Suneetha
Publicado: (2021)

Water and sanitation risk exposure in children under-five in Pakistan
por: Murtaza, Fowad, et al.
Publicado: (2021)

A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome
por: Hafiz, Maida, et al.
Publicado: (2019)

The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy
por: Amara, Suneetha, et al.
Publicado: (2017)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
por: Demirtas, Coskun O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6i9udscdg7u9t4o8fu3nvfjscs